FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Anders Olsson

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Geographic Areas

Sweden

Anatomy

Femoral Artery

Co-author Network

Publications

TOP 3
Payman Zamani; Weihang Bao; Peter Ganz; Scott Kinlay; Peter Libby; Anders G Olsson; Nader Rifai; Gregory G Schwartz
Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study.
Sung Kee Ryu; Gregory G Schwartz; Alain Tedgui; Sotirios Tsimikas; Weihang Bao; Joelle Benessiano; Ziad Mallat; Anders G Olsson
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Anders G Olsson; Christina Lindahl; Ingar Holme; Rana Fayyad; Ole Faergeman; JJ Kastelein; Matti J Tikkanen; Mogens Lytken Larsen; Terje R Pedersen
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Anders Olsson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Payman Zamani; Weihang Bao; Peter Ganz; Scott Kinlay; Peter Libby; Anders G Olsson; Nader Rifai; Gregory G Schwartz
Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study.
Journal of the American Heart Association 2013;2(1):e003103.
2012: Sung Kee Ryu; Gregory G Schwartz; Alain Tedgui; Sotirios Tsimikas; Weihang Bao; Joelle Benessiano; Ziad Mallat; Anders G Olsson
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Circulation 2012;125(6):757-66.
2011: Anders G Olsson; Christina Lindahl; Ingar Holme; Rana Fayyad; Ole Faergeman; JJ Kastelein; Matti J Tikkanen; Mogens Lytken Larsen; Terje R Pedersen
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2011;18(2):262-9.
2010: Anders G Olsson
HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2010;20(8):553-7.
2010: Terje R Pedersen; Nilo B Cater; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Christina Lindahl; Michael Szarek
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
The American journal of cardiology 2010;106(3):354-9.
2010: Anders G Olsson
Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
Expert opinion on pharmacotherapy 2010;11(10):1715-26.
2010: Ingar Holme; R Fayyad; Ole Faergeman; J J P Kastelein; Anders G Olsson; Matti J Tikkanen; Mogens Lytken Larsen; C Lindahl; Hallvard Holdaas; T R Pedersen
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Journal of internal medicine 2010;267(6):567-75.
2010: Anders G Olsson
Recent advances in preventing cardiovascular disorders by managing lipid levels.
F1000 medicine reports 2010;2():66.
2009: Matti J Tikkanen; Michael Szarek; Rana Fayyad; Ingar Holme; Nilo B Cater; Ole Faergeman; John J P Kastelein; Anders G Olsson; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
Journal of the American College of Cardiology 2009;54(25):2353-7.
2009: Scott Kinlay; Gregory G Schwartz; Anders G Olsson; Nader Rifai; Weihang Bao; Peter Libby; Peter Ganz
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
Atherosclerosis 2009;206(2):551-5.
2009: Anders G Olsson
Lipid lowering and aortic valve disease.
Current atherosclerosis reports 2009;11(5):377-83.
2009: Ingar Holme; Timo E Strandberg; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
Atherosclerosis 2009;205(2):522-7.
2009: Alexander E Fraley; Gregory G Schwartz; Anders G Olsson; Scott Kinlay; Michael Szarek; Nader Rifai; Peter Libby; Peter Ganz; Joseph L Witztum; Sotirios Tsimikas
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Journal of the American College of Cardiology 2009;53(23):2186-96.
2009: Ingar Holme; Michael Szarek; Nilo B Cater; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2009;16(3):315-20.
2009: Matti J Tikkanen; Ingar Holme; Nilo B Cater; Michael Szarek; Ole Faergeman; John J P Kastelein; Anders G Olsson; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
The American journal of cardiology 2009;103(5):577-82.
2009: Anders G Olsson
Is high HDL cholesterol always good?
Annals of medicine 2009;41(1):11-8.
2008: Anders G Olsson
NICE lipid modification guideline: both absolute and obsolete!
Heart (British Cardiac Society) 2008;94(10):1256-7.
2008: Anders G Olsson
Will CETP inhibition survive the demise of torcetrapib?
Current atherosclerosis reports 2008;10(2):97-9.
2008: Ingar Holme; Nilo B Cater; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Mogens Lytken Larsen; Christina Lindahl; Terje R Pedersen
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Annals of medicine 2008;40(6):456-64.
2008: Scott Kinlay; Gregory G Schwartz; Anders G Olsson; Nader Rifai; Michael Szarek; David D Waters; Peter Libby; Peter Ganz
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(1):142-7.
2007: Johnny Nijm; Margareta Kristenson; Anders G Olsson; Lena Jonasson
Impaired cortisol response to acute stressors in patients with coronary disease. Implications for inflammatory activity.
Journal of internal medicine 2007;262(3):375-84.
2007: Anders G Olsson; Gregory G Schwartz; Michael Szarek; Don Luo; Michael J Jamieson
Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).
The American journal of cardiology 2007;99(5):632-5.
2006: Gunilla Hollman; Anders G Olsson; Anna-Christina Ek
Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia.
The Journal of cardiovascular nursing 2006;21(2):103-8.
2005: Terje R Pedersen; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Fredrik S Bendiksen; Christina Lindahl; Michael Szarek; John Tsai
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2005;294(19):2437-45.
2005: Gregory G Schwartz; Anders G Olsson; Michael Szarek; Bill Sasiela
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.
Diabetes care 2005;28(10):2508-13.
2005: Bo Ziedén; Anders G Olsson
The role of statins in the prevention of ischemic stroke.
Current atherosclerosis reports 2005;7(5):364-8.
2005: Anders G Olsson; Gregory G Schwartz; Michael Szarek; Bill Sasiela; Michael D Ezekowitz; Peter Ganz; Michael F Oliver; David Waters; Andreas M Zeiher
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
European heart journal 2005;26(9):890-6.
2005: Johnny Nijm; Anders Wikby; Andrea Tompa; Anders G Olsson; Lena Jonasson
Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease.
The American journal of cardiology 2005;95(4):452-6.
2005: Margareta Kristenson; Anders G Olsson; Zita Kucinskiene
Good self-rated health is related to psychosocial resources and a strong cortisol response to acute stress: the LiVicordia study of middle-aged men.
International journal of behavioral medicine 2005;12(3):153-60.
2004: Wei Li; Anna Hellsten; Leif S Jacobsson; Henrik M Blomqvist; Anders G Olsson; Xi-Ming Yuan
Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits.
Journal of molecular and cellular cardiology 2004;37(5):969-78.
2004: Suzanne Lind; Anders G Olsson; Mats Eriksson; Mats Rudling; Gösta Eggertsen; Bo Angelin
Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment.
Journal of internal medicine 2004;256(5):406-12.
2004: Sotirios Tsimikas; Joseph L Witztum; Elizabeth R Miller; Bill Sasiela; Michael Szarek; Anders G Olsson; Gregory G Schwartz
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Circulation 2004;110(11):1406-12.
2004: Gunilla Hollman; Anna-Christina Ek; Anders G Olsson
Only one of four patients with familial hypercholesterolaemia reach cholesterol treatment goals in primary prevention.
Journal of internal medicine 2004;256(2):176-7.
2004: Scott Kinlay; Gregory G Schwartz; Anders G Olsson; Nader Rifai; Bill Sasiela; Michael Szarek; Peter Ganz; Peter Libby
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Circulation 2004;110(4):386-91.
2004: Gunilla Hollman; Anna-Christina Ek; Anders G Olsson; Carina Berterö
Meaning of quality of life among patients with familial hypercholesterolemia.
The Journal of cardiovascular nursing 2004;19(4):243-50.
2004: Leif S Jacobsson; Xi-Ming Yuan; Bo Ziedén; Anders G Olsson
Effects of alpha-tocopherol and astaxanthin on LDL oxidation and atherosclerosis in WHHL rabbits.
Atherosclerosis 2004;173(2):231-7.
2004: Anders G Olsson
Psychosocial factors and coronary heart disease.
Current atherosclerosis reports 2004;6(1):1-2.
2003: Scott Kinlay; Gregory G Schwartz; Anders G Olsson; Nader Rifai; Sally J Leslie; Bill Sasiela; Michael Szarek; Peter Libby; Peter Ganz
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Circulation 2003;108(13):1560-6.
2003: Lena Jonasson; Anders Wikby; Anders G Olsson
Low serum beta-carotene reflects immune activation in patients with coronary artery disease.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2003;13(3):120-5.
2003: Gunilla Hollman; Anders G Olsson; Anna-Christina Ek
Familial hypercholesterolaemia and quality of life in family members.
Preventive medicine 2003;36(5):569-74.
2003: H M Blomqvist; Anders G Olsson
Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia.
Scandinavian journal of clinical and laboratory investigation 2003;63(7-8):513-9.
2002: Anders G Olsson; Gregory G Schwartz; Lena Jonasson; C Linderfalk
Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
Acta physiologica Scandinavica 2002;176(2):147-50.
2002: David D Waters; Gregory G Schwartz; Anders G Olsson; Andreas M Zeiher; Michael F Oliver; Peter Ganz; Michael D Ezekowitz; Bernard R Chaitman; Sally J Leslie; Theresa Stern
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Circulation 2002;106(13):1690-5.
2002: Bertil Ekman; Torbjörn Lindström; Fredrik Nyström; Anders G Olsson; Göran Toss; Hans J Arnqvist
A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults.
European journal of endocrinology / European Federation of Endocrine Societies 2002;147(1):49-57.
2002: Gunilla Hollman; M Gullberg; Anna-Christina Ek; M Eriksson; Anders G Olsson
Quality of life in patients with familial hypercholesterolaemia.
Journal of internal medicine 2002;251(4):331-7.
2002: Lena Jonasson; Carina Linderfalk; Jadwiga Olsson; Anders Wikby; Anders G Olsson
Systemic T-cell activation in stable angina pectoris.
The American journal of cardiology 2002;89(6):754-6.
2002: Bo Ziedén; A Kaminskas; Margareta Kristenson; Anders G Olsson; Zita Kucinskiene
Long chain polyunsaturated fatty acids may account for higher low-density lipoprotein oxidation susceptibility in Lithuanian compared to Swedish men.
Scandinavian journal of clinical and laboratory investigation 2002;62(4):307-14.
2002: Anders G Olsson; Gregory G Schwartz
Early initiation of treatment with statins in acute coronary syndromes.
Annals of medicine 2002;34(1):37-41.
2001: Gregory G Schwartz; Anders G Olsson; Michael D Ezekowitz; Peter Ganz; Michael F Oliver; David Waters; Andreas M Zeiher; Bernard R Chaitman
Atorvastatin for acute coronary syndromes.
JAMA : the journal of the American Medical Association 2001;286(5):533-5.
2001: Gregory G Schwartz; Anders G Olsson; Michael D Ezekowitz; Peter Ganz; Michael F Oliver; David Waters; Andreas M Zeiher; Bernard R Chaitman; Sally J Leslie; T Stern
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2001;285(13):1711-8.
2000: Margareta Kristenson; C Lassvik; Björn Bergdahl; Z Kucinskiène; L Aizieniène; Z Bo; L S Elinder; Anders G Olsson
Ultrasound determined carotid and femoral atherosclerosis in Lithuanian and Swedish men: the LiVicordia study.
Atherosclerosis 2000;151(2):501-8.
1999: Torbjörn Lindström; Fredrik Nyström; Anders G Olsson; A M Ottosson; Hans J Arnqvist
The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus.
Diabetic medicine : a journal of the British Diabetic Association 1999;16(10):820-6.
1999: A Kaminskas; Bo Ziedén; B Elving; Margareta Kristenson; A Abaravicius; Björn Bergdahl; Anders G Olsson; Zita Kucinskiene
Adipose tissue fatty acids in men from two populations with different cardiovascular risk: the LiVicordia study.
Scandinavian journal of clinical and laboratory investigation 1999;59(3):227-32.
1999: Bo Ziedén; A Kaminskas; Margareta Kristenson; Z Kucinskienê; B Vessby; Anders G Olsson; U Diczfalusy
Increased plasma 7 beta-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(4):967-71.
1999: J Mölgaard; S Wärjerstam-Elf; Anders G Olsson
Efficacy and safety of simvastatin for high-risk hypercholesterolemia.
The American journal of cardiology 1999;83(7):1043-8.
1998: Gregory G Schwartz; Michael F Oliver; Michael D Ezekowitz; Peter Ganz; David Waters; J P Kane; M Texter; M L Pressler; D Black; Bernard R Chaitman; Anders G Olsson
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
The American journal of cardiology 1998;81(5):578-81.
1998: Wei Li; Xi-Ming Yuan; Anders G Olsson; Ulf T Brunk
Uptake of oxidized LDL by macrophages results in partial lysosomal enzyme inactivation and relocation.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(2):177-84.
1998: E Swahn; H von Schenck; Anders G Olsson
Omega-3 Ethyl Ester Concentrate Decreases Total Apolipoprotein CIII and Increases Antithrombin III in Postmyocardial Infarction Patients.
Clinical drug investigation 1998;15(6):473-82.
1998: Margareta Kristenson; K Orth-Gomér; Z Kucinskienë; Björn Bergdahl; H Calkauskas; I Balinkyniene; Anders G Olsson
Attenuated cortisol response to a standardized stress test in Lithuanian versus Swedish men: the LiVicordia study.
International journal of behavioral medicine 1998;5(1):17-30.
1997: Xi-Ming Yuan; W Li; Anders G Olsson; Ulf T Brunk
The toxicity to macrophages of oxidized low-density lipoprotein is mediated through lysosomal damage.
Atherosclerosis 1997;133(2):153-61.
1997: Margareta Kristenson; Bo Ziedén; Z Kucinskienë; L S Elinder; Björn Bergdahl; B Elwing; A Abaravicius; L Razinkovienë; H Calkauskas; Anders G Olsson
Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: concomitant cross sectional study of men aged 50.
BMJ (Clinical research ed.) 1997;314(7081):629-33.
1996: Anders G Olsson; Xi-Ming Yuan
Antioxidants in the prevention of atherosclerosis.
Current opinion in lipidology 1996;7(6):374-80.
1996: Jan Regnström; Göran Walldius; S Nilsson; L S Elinder; J Johansson; J Mölgaard; I Holme; Anders G Olsson; Jan Nilsson
The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
Atherosclerosis 1996;125(2):217-29.
1996: Xi-Ming Yuan; W L Anders; Anders G Olsson; Ulf T Brunk
Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis.
Atherosclerosis 1996;124(1):61-73.
1995: Anders G Olsson; T Pedersen; B Bergdahl
Trials of lipid-lowering therapy in secondary prevention of coronary heart disease.
Current opinion in lipidology 1995;6(6):369-73.
1995: Xi-Ming Yuan; Ulf T Brunk; Anders G Olsson
Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(9):1345-51.
1995: L S Elinder; K Hådell; J Johansson; J Mølgaard; I Holme; Anders G Olsson; Göran Walldius
Probucol treatment decreases serum concentrations of diet-derived antioxidants.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(8):1057-63.
1995: J Johansson; Anders G Olsson; L Bergstrand; L S Elinder; S Nilsson; U Erikson; J Mölgaard; I Holme; Göran Walldius
Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(8):1049-56.
1995: O Smedby; J Johansson; J Mölgaard; Anders G Olsson; Göran Walldius; U Erikson
Predilection of atherosclerosis for the inner curvature in the femoral artery. A digitized angiography study.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(7):912-7.
1994: Göran Walldius; U Erikson; Anders G Olsson; L Bergstrand; K Hådell; J Johansson; L Kaijser; C Lassvik; J Mölgaard; S Nilsson
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
The American journal of cardiology 1994;74(9):875-83.
1994: L Bergstrand; Anders G Olsson; U Erikson; I Holme; J Johansson; L Kaijser; C Lassvik; J Mölgaard; S Nilsson; G Stenport
The relation of coronary and peripheral arterial disease to the severity of femoral atherosclerosis in hypercholesterolaemia.
Journal of internal medicine 1994;236(4):367-75.
1994: Jan Regnström; Göran Walldius; K Hådell; J Johansson; I Holme; Anders G Olsson; Jan Nilsson
Influence of lipoprotein lipids, dietary fat and smoking on macrophage degradation of native and oxidized low density lipoprotein.
Atherosclerosis 1994;110(1):13-23.
1994: Torbjörn Lindström; P Eriksson; Anders G Olsson; H J Arnqvist
Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure.
Diabetes care 1994;17(7):719-21.
1994: Torbjörn Lindström; Anders G Olsson; H von Schenck; Lars Wallentin; H J Arnqvist
Insulin treatment improves microalbuminuria and other cardiovascular risk factors in patients with type 2 diabetes mellitus.
Journal of internal medicine 1994;235(3):253-61.
1993: L Bergstrand; U Erikson; I Holme; J Johansson; Anders G Olsson; J Mølgaard; S Nilsson; G Stenport; Göran Walldius
Reproducibility of quantitative arteriographic assessment of atherosclerosis in the femoral artery.
Acta radiologica (Stockholm, Sweden : 1987) 1993;34(6):612-7.
1993: O Smedby; N Högman; S Nilsson; U Erikson; Anders G Olsson; Göran Walldius
Two-dimensional tortuosity of the superficial femoral artery in early atherosclerosis.
Journal of vascular research 1993;30(4):181-91.
1993: Anders G Olsson
The clinical importance of silent ischaemia during exercise--new insights in different stages of coronary artery disease.
Journal of internal medicine 1993;233(4):315-9.
1993: Göran Walldius; Jan Regnström; Jan Nilsson; J Johansson; L Schäfer-Elinder; J Moelgaard; K Hådell; Anders G Olsson; LA Carlson
The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST).
The American journal of cardiology 1993;71(6):15B-19B.
1992: J Mölgaard; Ib C Klausen; C Lassvik; Ole Faergeman; Lars U Gerdes; Anders G Olsson
Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1992;12(8):895-901.
1992: J Mölgaard; M R Malinow; C Lassvik; A C Holm; Barbara M Upson; Anders G Olsson
Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication.
Journal of internal medicine 1992;231(3):273-9.
1991: J Mölgaard; B L Lundh; H von Schenck; Anders G Olsson
Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia.
Atherosclerosis 1991;91 Suppl():S21-8.
1990: G Wahlberg; Göran Walldius; Anders G Olsson; P Kirstein
Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia.
Journal of internal medicine 1990;228(2):151-7.
1990: Anders G Olsson; G Ruhn; U Erikson
The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.
Journal of internal medicine 1990;227(6):381-90.
1990: J Mölgaard; M Carlsson; Jan Nilsson; Anders G Olsson
Decreased mitogenic activity in hypercholesterolaemic plasma.
Journal of internal medicine 1990;227(5):339-45.
1990: Torbjörn Lindström; H J Arnqvist; Anders G Olsson
Effect of different insulin regimens on plasma lipoprotein and apolipoprotein concentrations in patients with non-insulin-dependent diabetes mellitus.
Atherosclerosis 1990;81(2):137-44.
1990: J Mölgaard; H von Schenck; C Lassvik; T Kuusi; Anders G Olsson
Effect of fish oil treatment on plasma lipoproteins in type III hyperlipoproteinaemia.
Atherosclerosis 1990;81(1):1-9.
1989: G Ruhn; U Erikson; Anders G Olsson
Prevalence of femoral atherosclerosis in asymptomatic men with hyperlipoproteinaemia.
Journal of internal medicine 1989;225(5):317-23.
1989: J Mölgaard; H von Schenck; Anders G Olsson
Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia.
European journal of clinical pharmacology 1989;36(5):455-60.
1988: Göran Walldius; LA Carlson; U Erikson; Anders G Olsson; J Johansson; J Mölgaard; S Nilsson; G Stenport; L Kaijser; C Lassvik
Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
The American journal of cardiology 1988;62(3):37B-43B.
1988: J Mölgaard; H von Schenck; Anders G Olsson
Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia.
European heart journal 1988;9(5):541-51.
1988: U Erikson; G Helmius; Anders Hemmingsson; G Ruhn; Anders G Olsson
Repeat femoral arteriography in hyperlipidemic patients. A study of progression and regression of atherosclerosis.
Acta radiologica (Stockholm, Sweden : 1987) 1988;29(3):303-9.
1988: Anders G Olsson; L Holmquist; Göran Walldius; K Hådell; LA Carlson; Gabriele Riccardi; Paolo Rubba; Paolo Pauciullo; M Mancini
Serum apolipoproteins, lipoproteins and fatty acids in relation to ischaemic heart disease in northern and southern European males.
Acta medica Scandinavica 1988;223(1):3-13.
1987: Anders G Olsson
Angiographic evidence that treatment of lipoprotein abnormalities prevents progression of coronary atherosclerosis.
European heart journal 1987;8 Suppl E():55-8.
1984: Anders G Olsson; P Kirstein; B Eklund; H Johnsson; Göran Walldius
[Ineffectiveness of Naudicelle in intermittent claudication].
Läkartidningen 1984;81(51):4855-7.
1980: P Kirstein; T Jogestrand; H Johnsson; Anders G Olsson
Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis.
Atherosclerosis 1980;36(4):471-80.